Sumatriptan

Dosage ;

Sumatriptan Brands

Brand Name Manufacturer Name Distributor Drug Strength Packaging Formulation Formulation Strength Price
Imigram

NB; Not Imigran

 GSK Pharmaceuticals GSK Specialities Ltd. 100mg 6s Tablet per tablet KES 691
Sumatriptan
Mode Of Action

Serotonin (5HTI) agonist
Drug Indication Migraine (acute), cluster headache
Precautions Renal, hepatic, neurological and CV disorders, epilepsy, sulphonamide sensitivity
Contra-Indications Uncontrolled hypertension, SC use in patients with ischaemic heart disease, concomitant use with ergotamine preparations, management of hemiplegic or basilar migraine, IV use.
Side Effects Burning sensation, tingling, warm/hot sensation, visual disturbances, nasal
Special Information It is structurally as well as pharmacologically related to serotonin, (5-hydroxytryptamine, 5HT) differing structurally from serotonin mainly by the substitution of methane sulfonamide for the alcohol group on the indication sole ring.
Drug Category DRUGS ACTING ON CNS
Drug Sub-Category Anti-migraine drugs

Dosing: Adult

Migraine:

Oral: A single dose of 25 mg, 50 mg, or 100 mg (taken with fluids). If a satisfactory response has not been obtained at 2 hours, a second dose may be administered. Results from clinical trials show that initial doses of 50 mg and 100 mg are more effective than doses of 25 mg, and that 100 mg doses do not provide a greater effect than 50 mg and may have increased incidence of side effects. Although doses of up to 300 mg/day have been studied, the total daily dose should not exceed 200 mg. The safety of treating an average of >4 headaches in a 30-day period have not been established.

Intranasal: A single dose of 5 mg, 10 mg, or 20 mg administered in one nostril. A 10 mg dose may be achieved by administering a single 5 mg dose in each nostril. If headache returns, the dose may be repeated once after 2 hours, not to exceed a total daily dose of 40 mg. In clinical trials, a greater number of patients responded to initial doses of 20 mg versus 5 or 10 mg. The safety of treating an average of >4 headaches in a 30-day period has not been established.

SubQ: Initial: Up to 6 mg; may repeat if needed ≥1 hour after initial dose (maximum: Two 6 mg injections per 24-hour period). However, controlled clinical trials have failed to document a benefit with administration of a second 6 mg dose in nonresponders.

Cluster headache: SubQ: Initial: Up to 6 mg; may repeat if needed ≥1 hour after initial dose (maximum: Two 6-mg injections per 24-hour period)

Dosing: Geriatric

Not recommended due to increased potential for adverse effects.

Dosing: Renal Impairment

Dosage adjustment is not necessary.

Dosing: Hepatic Impairment

Mild-to-moderate hepatic impairment:

Oral: Bioavailability of oral sumatriptan is increased with liver disease. If treatment is needed, do not exceed single doses of 50 mg.

Nasal spray: Has not been studied in patients with hepatic impairment, however, because the spray does not undergo first-pass metabolism, levels would not be expected to be altered.

Subcutaneous: Has been studied and pharmacokinetics were not altered in patients with hepatic impairment compared to healthy patients.

Severe hepatic impairment: Oral, nasal, and subcutaneous (limited to Imitrex® injection, per prescribing information) formulations are contraindicated with severe hepatic impairment